報價延遲最少15分鐘:2025/07/20 13:06 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.22 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.82/-3.12
|
|
企業價值
674.27M
|
| 資產負債 |
|
每股賬面淨值
6.41
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
36.56M
|
|
每股收益
0.17
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 13:06 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner. |
